Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05304988
Other study ID # EFT_Adolescents
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 7, 2020
Est. completion date March 6, 2023

Study information

Verified date March 2022
Source The Hong Kong Polytechnic University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There is increasing evidence of interventions shown to be effective to promote physical activity in adolescents with cancer. Nevertheless, adolescents with cancer become physically inactive after the end of the interventions. These interventions emphasized heavily on interventionists' role to assess adolescents' physical fitness and prescribe exercises. After the intervention, the adolescents were unable to follow the previous exercise prescriptions due to their changing medical conditions. To promote physical activity sustainably, it is vital to develop a patient-based assessment tool to allow adolescents with cancer to self-assess their own appropriate levels of physical activity that they could perform. However, a review of literature indicates a lack of such a tool.


Description:

A cross-sectional study design will be used. A convenience sample of 400 adolescents who (1) are aged 13-18; (2) are diagnosed with cancer; (3) can communicate in Cantonese and read Chinese will be recruited in Hong Kong Children's Hospital. The outcome measures will include demographic characteristics, pain scores, cardiopulmonary function measurements, EFT scores and ratings of the oncologist for the fitness of subjects for physical activity.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 400
Est. completion date March 6, 2023
Est. primary completion date March 6, 2023
Accepts healthy volunteers No
Gender All
Age group 13 Years to 18 Years
Eligibility Inclusion Criteria: - Aged 13-18 - are diagnosed with cancer - are able to communicate in Cantonese and read Chinese Exclusion Criteria: - with physical or cognitive impairment and learning problems as identified from the medical records

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Testing of the EFT
A research committee which composes of a paediatric oncologist, a ward manager, an assistant professor and a research assistant will be set up. The committee will develop specific questions in EFT and design and implement the clinical Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The oncologist will rate the subject with the most appropriate level of physical activity on a 4-point scale.

Locations

Country Name City State
Hong Kong Katherine Lam Hong Kong Hong Kong,China

Sponsors (1)

Lead Sponsor Collaborator
The Hong Kong Polytechnic University

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary The EFT scores Subjects will be asked to mark their responses for the EFT items in the second draft just before their scheduled oncologist routine visit. The scale ranges from 1 to 4. Higher scores indicate that the subjects are fit for a higher level of physical activity. Just before their scheduled oncologist routine visit
Secondary Numerical Rating Scale (NRS) for pain Subjects will be asked to mark their pain level on the NRS according to their experience just before their scheduled oncologist routine visit. The scale ranges from 0 to 10. Higher scores represent a higher level of pain. Just before their scheduled oncologist routine visit
Secondary The oncologists' rating for physical activity The oncologists will rate the subject with the most appropriate intensity level of physical activity on a 4-point scale. The scale ranges from 1 to 4. Higher scores indicate that the subjects are fit for a higher level of physical activity. Just before their scheduled oncologist routine visit
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery